Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2022-12-08 Legal Proceedings Report
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated December 8, 2022, from Ipsen, announcing the results of a Phase III clinical trial (CONTACT-01) for a drug (cabozantinib). It details that the primary endpoint (overall survival) was not met, provides context on the drug's safety profile, and states that detailed results will be presented at a future medical congress. This type of announcement, focusing on the immediate outcome of a clinical trial, is characteristic of a press release related to research and development progress. It is not a full Annual Report (10-K), a formal Earnings Release (ER) which focuses on financial performance, or a formal Investor Presentation (IP). Since it is a specific announcement about clinical trial data, it fits best under the general category of Regulatory Filings (RNS) as a broad communication of material information, or potentially a specialized communication if one existed. Given the provided definitions, and since it is a specific, non-financial, non-governance announcement about R&D progress, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it strongly resembles an 'Earnings Release' in format, but the content is clinical trial data, not financial results highlights. However, since it is a direct communication of material, non-financial, non-governance news, RNS serves as the best fit among the options for a press release detailing clinical trial outcomes.
2022-12-08 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen dated December 8, 2022, announcing the results of a Phase III clinical trial (CONTACT-01) for one of its drugs (cabozantinib). It details that the trial did not meet its primary endpoint (overall survival) and provides context on the drug, the trial design, and company background. This content—announcing clinical trial outcomes, efficacy, and safety profiles—is characteristic of an Earnings Release (ER) or a specific type of corporate announcement related to product development milestones. Since it is a specific announcement of financial/operational results (clinical trial outcome) rather than a full quarterly report (IR) or a general transcript (CT), the most fitting category is Earnings Release (ER), which covers initial announcements of periodical results/key operational milestones. It is not a formal regulatory filing like a 10-K, nor is it a presentation (IP) or a management discussion (MDA), although it contains elements of both. It is a direct announcement of a key operational result.
2022-12-08 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information relative to the total number of voting rights and shares composing the share capital" and provides a table detailing the total number of shares and voting rights as of a specific date (October 31, 2022). This type of regular disclosure, mandated by French commercial code and AMF regulations, relates to the structure of voting rights and share capital. While it touches upon share capital, its primary focus is the monthly disclosure of voting rights, which is a specific regulatory requirement often falling under general regulatory announcements or specific share/voting right disclosures. Given the options, it is most closely related to general share/capital structure information, but it is not a formal declaration of voting results (DVA) which typically follows a meeting, nor is it a general capital change announcement (SHA). Since it is a mandatory, periodic disclosure concerning the composition of voting rights, it fits best under the general 'Regulatory Filings' (RNS) category as a specific, recurring regulatory disclosure that doesn't match the other specific codes like DIV, SHA, or DVA. The document length is short, but it is the report itself, not an announcement of a report.
2022-11-10 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references compliance with French regulations (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of October 31, 2022. This type of regular disclosure concerning the total share capital and voting rights structure is a specific regulatory filing requirement, often related to capital structure changes or mandatory periodic updates. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it deals directly with the composition of the capital and voting rights, it most closely aligns with a notification about the share capital structure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a mandatory monthly disclosure detailing the total number of shares and voting rights, as this information underpins capital structure reporting. It is a direct report of capital structure data, not an announcement of a report (RPA/RNS).
2022-11-10 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen dated November 9, 2022, announcing positive Phase III clinical trial results (NAPOLI 3) for their drug Onivyde® in treating metastatic pancreatic ductal adenocarcinoma. It details the trial endpoints met, safety profile, and the intention to file a supplemental New Drug Application (NDA) with the FDA. It also includes extensive U.S. Important Safety Information (ISI) and Boxed Warnings, which are standard components of drug announcements or prescribing information summaries released by pharmaceutical companies. This content is characteristic of an announcement reporting significant clinical data, often preceding a formal regulatory filing or being released alongside an Earnings Release (ER) or as a standalone update. Since it focuses purely on the clinical trial outcome and the next regulatory step (filing an NDA), and is not a full financial report (10-K/IR), a transcript (CT), or a general management discussion (MDA), the most fitting category is one related to specific company announcements. Given the focus on a major clinical development and the intent to file with the FDA, it functions as a significant corporate announcement. It is not a generic Regulatory Filing (RNS) because it is highly specific. It is not an Earnings Release (ER) as it focuses on clinical data, not period financials. It is most closely aligned with a major corporate update that might accompany an ER or be released independently. In the absence of a specific 'Clinical Trial Results Announcement' category, this type of detailed, non-financial, non-governance announcement often falls under the general 'Regulatory Filings' (RNS) category if it doesn't fit elsewhere, or sometimes an 'Investor Presentation' (IP) if it were a slide deck. However, since it is a press release detailing trial success and future regulatory steps, and it is not a report itself, 'RNS' serves as the best fit among the provided options for a significant, non-standard announcement.
2022-11-09 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated November 9, 2022, from Ipsen, announcing positive Phase III clinical trial results (NAPOLI 3) for their drug Onivyde® in treating metastatic pancreatic cancer. It details efficacy endpoints (Overall Survival, Progression-Free Survival), safety profiles, and plans for regulatory submission (FDA). This content—announcing key financial/clinical results and providing management commentary—is characteristic of an Earnings Release (ER) or a detailed Management Discussion/Analysis (MDA). Since it focuses heavily on the clinical trial results and the immediate next steps (regulatory submission), it functions as a primary announcement of performance/results, which aligns best with the 'Earnings Release' (ER) definition, even though it's clinical data rather than pure financial figures. It is not a full Annual Report (10-K), a transcript (CT), or a formal regulatory filing announcement (RPA/RNS) that just points to another document. The length (nearly 20,000 characters) suggests it is more substantial than a brief ER, but the nature of announcing trial success fits the ER category better than MDA, which usually explains past performance in detail. Given the context of a major clinical milestone announcement, ER is the most appropriate fit among the options provided for a significant, time-sensitive announcement of positive data.
2022-11-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.